• Avid Radiopharmaceuticals has raised $34.5M in Series D financing to advance 18F-AV-45, a first-in-class amyloid imaging agent for Alzheimer’s disease. The financing was led by Alta Partners, AllianceBernstein, Safeguard Scientifics, Pfizer Venture Investments, Lilly Ventures, RK Ventures Group and BioAdvance (Biotechnology Greenhouse of Southeastern Pennsylvania). [BusinessWire]

• Sagent Pharmaceuticals raised $30M in financing this week to extend its total Series A to $110M. Sagent has nine injectable drugs for cardiovascular and anti-bacterial treatments on the market and launched an injectable Cefazolin in February. The round was led by Vivo Ventures. [PRNewswire]

• PolyMedix (OTC BB: PYMX) has entered into an agreement with Dutchess Equity Fund, LP for up to $10M of financing through an equity line facility. The company’s lead drug is PMX-30063, a small molecule mimetic of human host-defense proteins which functions as an antibacterial, but without propensity for resistance. [BioSpace]

• Vical (VICL) says it will sell $15.4M of securities to Federated Kaufmann Fund and another unnamed investor for net proceeds of about $14.6M USD in a registered direct offering. Vical will use the funds to advance its Phase 3 trial of Allovectin-7, an immunotherapeutic for metastatic melanoma, a Phase 3 trial of CB01-202 for CMV and a Phase I study of IPT1-101 for pandemic flu. [FierceBiotech]

• Paladin Labs (PLB.TO) said it’s raising C$51M ($44.M USD) to finish its acquisition of Dexedrine, fund the joint venture partnership with Isotechnika and for other purposes. The sale will be to Desjardins Securities, TD Securities ans Joddes Limited, which currently owns about 42% of the Paladin’s outstanding shares. [Reuters]

• Australia-based Starpharma Holdings has raised $2M, the second tranche of a share placement making the total $7.1M. Starpharma’s lead product is VivaGel®, a gel-based formulation of a nano-pharmaceutical under development as a vaginal microbicide to prevent the transmission of sexually transmitted infections, including HIV and genital herpes. [The Sydney Morning Herald]

• PURE Bioscience will sell up to 1,418,440 of newly issued shares of its common stock and warrants for a total of $3M. PURE is the maker of the anti-microbial, silver dihydrogen citrate (SDC). [Company website]

Anonymous Tip? Comments? Contact us at: hr@iguanabio.com

Image from wikimedia

Related Posts